{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.77","upperLimit":"75.99","value":"53.85"},{"groupId":"OG001","lowerLimit":"6.01","upperLimit":"50.48","value":"25"},{"groupId":"OG002","lowerLimit":"39.76","upperLimit":"91.10","value":"74.59"},{"groupId":"OG003","lowerLimit":"15.90","upperLimit":"67.50","value":"42.74"},{"groupId":"OG004","lowerLimit":"16.63","upperLimit":"53.71","value":"34.78"},{"groupId":"OG005","lowerLimit":"18.96","upperLimit":"53.13","value":"35.86"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"description":"The 1-year Overall Survival will be estimated using Kaplan-Meier methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Ewing's Sarcoma"},{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Rhabdomyosarcoma"},{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Non-Rhabdomyosarcoma Soft Tissue Sarcoma"},{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Wilms Tumor"},{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Rare Tumors"},{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG005","title":"Osteosarcoma"}],"paramType":"NUMBER","populationDescription":"All patients who met the evaluable for response criteria outlined in section 9.4 of the ADVL1622 protocol.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}